Home › Chronic Urticaria
Pag-aaral pangklinika para sa Chronic Urticaria na nagre-recruit sa U.S.
8 pag-aaral para sa Chronic Urticaria ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Ayos sa estado
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06865651A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06868212An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06927999A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT07219615A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update May 11, 2026 · NCT07408219A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Abr 21, 2026 · NCT07540910Remibrutinib in Real-world Clinical Practice
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 16, 2026 · NCT07358364Remibrutinib in Real-world Clinical Practice - a US Sub-study
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT07358780Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.